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INTRODUCTION
Gastric Fundic Gland Polyps (FGPs) are sporadic
gastric polyps. They are found in upto 84% of patients
with Familial Adenomatous Polyposis (FAP). These
FGPs occur almost exclusively in patients without
H. pylori infection.1 They have always been regarded as
benign lesions, with low-grade dysplasia (intraepithelial
neoplasia) at the most. There have, however, been case
reports of FGPs harbouring severe dysplasia or even
gastric adenocarcinoma, particularly when associated
with FAP, but also in one sporadic gastric polyp. 
Proton pump inhibitors are used widely in the
management of acid-related disorders. They are
effective for the majority of patients with
gastroesophageal reflux disease, peptic ulcer disease
and non-steroidal anti-inflammatory drug-induced
gastropathy. They are considered safe but there are
concerns about the possibility of an association with
cancer, infection and gastric atrophy. Long-term usage
is difficult to define and most patients take PPIs non-
continuously. Self-prescription of medications is
common in developing countries and a substantial
proportion of long-term users appear not to have a clear
indication for their therapy. Also, medications are freely
available on the counters of pharmacies without
prescription. We report here a case of long-term PPIs
use, associated with Gastric Corpus Polyps (GCPs), in
a patient with a history of dysmotility symptoms.
CASE REPORT
A 51-year-old man presented with regurgitation,
belching and retrosternal heaviness. He was on PPI
(Losec) 40 mg OD, off and on, for the last 17 years. An
Esophago-gastroduodenoscopy (EGD) revealed mild
pangastric erythema and several whitish pink sessile
polyps (< 1 cms) in the gastric corpus (Figure 1).
Histology of the biopsies taken from the antrum and
corpus revealed mild non-specific inflammatory cell
infiltrate (Figure 2-3). Helicobacter pylori were not seen.
Sections from sessile polyp revealed polypoid fragments
of glandular epithelium with dilated glands. No evidence
of metaplasia, dysplasia or malignancy was noted in
specimens. PCR for 16S rRNA gene of H. pylori was
negative in biopsy specimens removed from antrum,
corpus and fundus of the stomach. His fasting serum
gastrin was 180 pg/ml (normal range 13-115 pg/ml). In
March 1992, he had a barium meal examination for
similar complaints that showed a large lobulated mass in
the mid esophagus–a leiomyoma. This was confirmed
on an EGD examination demonstrating a bi-lobed
extrinsic hemispherical defect mostly on the anterior
wall extending from 26 cms from incisors to 34 cms.
Esophageal mucosal covering was intact with increased
vascularity. MRI demonstrated a mass involving 10 cms
segment of esophagus below the aortic arch. He had
surgical removal of leiomyoma of esophagus in July
1992. However, after surgery symptoms of reflex
became worse. He took PPIs, which gave him some
symptomatic relief but epigastric discomfort persisted. A
repeat barium swallow examination demonstrated
motility disorder involving distal half and relative
dilatation of mid portion of esophagus, which did not
demonstrate contractility. Subsequent EGDs did not
demonstrate any pathology dilatation of the mid portion
of esophagus.
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CASE REPORT
DISCUSSION
In our patient, there was a history of having surgery for
esophageal leiomyoma, which is known to predispose to
esophageal dysmotility. However, dysmotility tends to
improve following surgical removal of leiomyoma.2 The
long-term use of PPI for 16 years predisposed him to
develop gastric corpus polyps (GCPs). This is
uncommon association described in the western
literature. However, earlier reports of PPI induced FGPs
are from fundus.3 This is in contrast to hyperplastic
gastric polyps associated with H. pylori infection, which
are commonly described in corpus but may be
distributed widely in the stomach. It is known that FGPs
are not associated with H. pylori infection.4 In this case,
histology demonstrated mild non-specific inflammatory
cell infiltrate and H. pylori were not seen on histology.
Proton pump inhibitors have some bacteriostatic activity
against H. pylori both in vitro and in vivo and also inhibit
urease activity in vitro. It is also known that treatment
with PPI is detrimental to H. pylori at both the antrum and
corpus.  However, PCR for 16S rRNA of H. pylori was
conducted on the gastric biopsies obtained from antrum,
corpus and fundus5 to rule out concomitant H. pylori
infection predisposing to GCPs. In a previous study,
diagnostic yield of PCR for 16S rRNA (16S PCR) gene
of H. pylori on gastric tissue was higher than Rapid
Urease Test (RUT) and histology in patients on PPI and
H2RB with H. pylori infection.6 The 16S PCR for H. pylori
was negative from all sites. 
Proton pump inhibitors are a benzimidazole substituted
anti-secretory agents. They decrease parietal cell acid
secretion by inhibiting hydrogen/potassium-exchanging
adenosine triphosphatase. Potent PPIs are preferred for
GERD. The main concern with the long-term proton
pump inhibitor use includes profound hypoacidity and
hypergastrinemia.7 Proton pump inhibitors induced
hypergastrinemia has been associated with the
development of FGPs.8 These FGPs are most
commonly reported in the fundus or acid secreting
mucosa. Histologically, FGPs are characterized by
distorted glandular architecture consisting of microcysts,
mostly lined with chief and parietal cells.9 Also, in
humans, diffuse, linear, or micronodular hyperplasia of
enterochromaffin-like cells is observed in 10–30% of
chronic PPI users, in particular in H. pylori positive
patients with more markedly increased gastrin levels.10
The elevated serum gastrin level in our case was
consistent with the chronic PPI use.10 Most of these
patients have moderate to severe inflammation of the
body mucosa, often with atrophic changes. However,
dysplasia or invasive carcinoid formation has never
been described in long-term PPI users. The patients
developing such polyps should have a lower
gastrointestinal endoscopy to exclude the possibility of
familial polyposis when harbouring severe dysplasia or
gastric adenocarcinoma.
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Figure 1: Gastric corpus polyps. Figure 2: Microcysts lined by fundic epithelium
overlying foveolae are shortened H and E (x 20).
Figure 3: Polypoid fragment of gastric mucosa
showing microcysts H and E (x 20).
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